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ABSTRACT
Objective: The objective of the present study is to explore novel drug lead constituents from Andrographis paniculata for the treatment of Parkinson’s 
disease.
Methods: Phytoconstituents from A. paniculata were screened, and their activity against the monoamine oxidase B (MAO-B) protein was analyzed using 
Molegro Virtual Docker software. The binding energy and interaction of the phytoconstituents with the protein were analyzed. The phytoconstituents 
were also analyzed for their compliance toward Lipinski’s rule of five.
Results: Molecular docking studies were performed using Molegro Docking software. The compound neoandrographolide exhibited more potent 
inhibitory activity with a MolDock score of −126.78 Kcal/mol compared to that of the standard drug Zelapar which exhibited a MolDock score of 
−49.95 Kcal/mol. The docked pose of the compound neoandrographolide fits exactly at the active site with a maximum number of H-bond interactions.
Conclusion: The present study suggests that neoandrographolide could be used as a potent inhibitor of MAO-B protein. However, it has to be validated 
using in-vivo and in-vitro studies to suggest the potency of neoandrographolide to inhibit the target protein, which could make neoandrographolide as 
an effective drug lead for the treatment of Alzhemier’s disease.
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INTRODUCTION
Parkinson’s disease is a neurodegenerative disease of the central 
nervous system which mainly affects the motor system. In 
industrialized countries, 0.3% of the population is being affected by 
Parkinson’s disease [1]. The Parkinson’s disease is associated with the 
degradation of nigrostriatal dopamine neurons, exhibiting symptoms 
such as bradykinesia, resting tremor, postural instability and dementia 
occurring in the advanced stages of the disease [2]. The symptoms 
of main motor systems are collectively called as Parkinsonism. The 
Parkinsonism was sub-classified into four types. They are primary 
(idiopathic), secondary (acquired), hereditary Parkinsonism, and 
multiple system degeneration [3]. Idiopathic, i.e., primary parkinsonism 
is common. Mutation in one of the several genes is found to be evident 
in more than 10% of Parkinson’s cases. It is stated that the inhibition 
of key metabolic enzyme monoamine oxidase B (MAO-B) suppress the 
progression of neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s disease [4,5].
MAO-B is an enzyme, which was coded by the gene MAO-B. MAO-B 
presents throughout the body but have higher expression level in liver 
and brain. It is located in the outer mitochondrial layer and primarily 
present in non-neuronal cells such as radial glial and astrocytes [6]. It 
has bipartite hydrophobic cavities with the volume nearly 700 Å3. The 
first cavity (~290 Å3) is act as the entrance cavity and the second cavity 
(~390 Å3) is the active site of the MAO-B [7].
The major function of MAO-B is generating hydrogen peroxide, 
which leads to the mitochondrial dysfunction and induces oxidative 
stress [8]. It degrades several chemicals such as benzylamine and 
phenylethylamine, which also including dopamine. The reduce in 
neurotransmission of dopamine leads to the cognitive decline [9]. In 
addition to that, during aging the dopamine levels decrease and the 
MAO-B expression is increased by three-folds [10]. These discoveries 
propose that the inhibition of MAO-B and maintenance of dopamine are 
the strategy to recover the cognitive function. The inhibition of MAO-B 
at the earlier stages of Parkinson’s disease was proficient of stumbling 
or adjourning the subsequent mechanism involved [11]. So, there has 
been an emergence of novel drug discovery to target the MAO-B for 
Parkinson’s disease.
Plant-derived phytochemicals have been traditionally used as a 
natural remedy in the treatment of diverse ailments. They are 
the backbone of traditional medicine. Usage of medicinal plants 
demonstrates promising and potential effect in treatment against 
many human diseases, due to the recognition that the natural products 
are non-toxic. In this content, there is an interest in developing novel 
lead molecules from plant sources because of their higher biological 
activity, safety, and lower cost as compared to the synthetic drugs.
Andrographis paniculata is a herbaceous plant, belongs to the family 
of Acanthaceae, whose roots and leaves are used as remedies over 
countries [12]. A. paniculata is reported to possess potent biological 
properties such as antimicrobial, anti-snake venom, antioxidant, 
immunomodulatory, anti-inflammatory, hypoglycemic, and 
cardiovascular activity [13]. So, the phytoconstituents from A. paniculata 
could therefore act as the good source of medicinal beneficial over the 
synthetic drugs.
In this study, we aim at exploring novel phytoconstituents from 
A. panicualta as potential lead molecules against the target protein 
MAO-B using Molegro Virtual Docker.
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The structure of phytoconstituents from A. paniculata was retrieved 
from Pubchem (https://pubchem.ncbi.nlm.nih.gov/) and Chemspider 
database (http://www.chemspider.com/). The compounds were 
converted into a comfortable format (.sdf) using Open Babel tool. The 
energy-minimized structure was used for docking studies.
Protein preparation
The three dimensional crystal structure of the MAO-B was taken from 
Protein DataBank (http://www.rcsb.org/pdb/). The PDB ID of the target 
protein is 4CRT. The bonds, bond orders, explicit hydrogen, charges 
(calculated by Molegro Virtual Docker), flexible torsion, and Tripos atom 
types were assigned if they were missing using “Protein Preparation” 
module of Molegro Virtual Docker for the protein MAO-B (Fig. 1).
Molecular docking
Molegro Virtual Docker works on the basis of MolDock SE search 
algorithm. The docking algorithm was set at a maximum iteration of 
1500 with a simple evolution size of 50 and minimum of 5 runs. The 
population size was set at 50 with energy threshold of 100 at each step. 
The least minute was set as 10 minutes, the torsions/translations/
rotations of the ligand-protein interaction were tested and the one 
giving lower energies is chosen for further studies. The bond flexibility 
of the ligands was fixed, and the side chain flexibility of the amino acids 
in the binding cavity was set with a tolerance of 1.10 and strength of 
0.90 for docking simulations. Root-mean-square deviation threshold 
for multiple cluster poses was set at <2.00.
The re-ranking score function is estimated more expensive than the 
scoring function used during the docking simulation, but it is commonly 
better than the docking score function at analyzing the best pose among 
several poses originating from the same ligand [14]. Binding affinities 
were estimated using Molegro data Modeler The scoring function used 
by MolDock is derived from the piecewise linear potential scoring 
functions which further improves these score with a new H-bonding 
term and new charge schemes [15].
Lipinski’s rule of five
For any molecule to be used as a drug, it has to follow Lipinski’s rule 
of five [12] which states that poor absorption or permeation are more 
likely when, (i) There are more than 5 H-bond donors, (ii) the molecular 
weight is over 500, (iii) the Log P (cLog P) is over 5, and (iv) there are 
more than 10 H-bond acceptors. Compound classes that are substrates 
for biological transporters are exceptions to the rule.
The above-listed phytochemicals which showed an affinity toward 
MAO-B were analyzed for their compliance to the Lipinski’s rule of five 
using OECD QSAR toolbox [16]. The QSAR toolbox is an open source 
software to analyze the phytochemical properties of compounds. 
RESULTS
Natural products derived from medicinal plants and their synthetic 
derivatives have been used as a good lead molecule [17]. A. paniculata 
has a number of active constituents which exhibits significant biological 
activities such as anti-inflammatory, immune stimulating, and liver 
protection activity [18]. Docking analysis was carried out for the 
phytoconstituents selected from A. paniculata against the target protein 
MAO-B using Molegro Docking Software so as to evaluate the efficacy 
of these compounds in suppressing the activity of target protein. The 
MolDock score of the phytoconstituents of A. paniculata was displayed 
in Table 1.
H-bond interaction
The strength of interaction between the compound and the protein 
is dependent on the number of H-bonds existing between them. The 
number of H-bonds interactions were calculated and tabulated in Table 2.
From the results, it was evident that four phytochemicals namely 
14-deoxy-11,12-didehydroandrographolide, andrographoside, neo-
andrographolide, and stigmasterin showed interaction with the target 
enzyme, whereas the rest of the phytochemicals did not show up any 
significant interactions with the protein of interest. Among these, 
compounds such as 14-deoxy-11, 12-didehydroandrographolide, 
andrographoside, and neoandrographolide showed a greater affinity 
Table 1: MolDock score for phytoconstituents of A. paniculata against target protein (MAO-B)
S. No Compound MolDock score (Kcal/mol) Re-rank score (Kcal/mol) H-bond (Kcal/mol)
1 Neoandrographolide −126.78 −51.9371 −14.3599
2 Stigmasterin −118.141 −89.62 −2.5
3 14-deoxy-11,12-didehydroandrographolide −116.945 −63.8776 −15.0094
4 Andrographoside −113.875 −72.9157 −9.44802
5 Andrographolide −95.4598 −84.2812 −5.27447
6 Isoandrographolide −89.8945 −72.8517 −7.25545
7 Deoxyandrographolide −87.8172 −73.6136 −2.7837
8 Zelapar (standard drug) −49.9563 −10.6736 −0.12296
9 Andrographan 202 1553.43 0
10 14-deoxyandrographolide 8118.18 241.916 2.06533
A. paniculata: Andrographis paniculata, MAO-B: Monoamine oxidase B
Table 2: H-bond interaction of the phytoconstituents of A. paniculata with the target protein (MAO-B)
S. No Compound Number of H-bonds H-bond interaction site
1 14-deoxy-11,12-didehydroandrographolide 11 Thr 408 A, Gln 409A, Asn 170 B, Glu 176 B, Thr 177 B, His 178 B
2 Andrographan - -
3 Andrographolide 4 Thr 408 A, Gln 409 A, Thr 177 B
4 Andrographoside 8 Lys 148 B, Asn 170 B, Gly 319 B, Glu 320 B, Leu 345 B, His 347 B
5 14-deoxyandrographolide 11 Thr 408 A, Gln 409 A
6 Deoxyandrographolide 3 Thr 408 A, Lys 149 B, Thr 177 B
7 Isoandrographolide 7 Asn 145 A, Gly 405 A, Thr 408 A, Gln 409 A, Thr 177 B, His 178 B
8 Neoandrographolide 12 Trp 135A, Glu 141A, Thr 408 A, Gln 409 A, Arg 412 A, Lys 149 B, 
Thr 177 B, His 178 B
9 Stigmasterin 2 Glu 159 B
10. Zelapar (standard drug) 1 Gln 409 B
A. paniculata: Andrographis paniculata, MAO-B: Monoamine oxidase B
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with more number of H-bond interactions with 6, 6 and 8 aminoacid 
residues, respectively, present in the binding pocket of the target enzyme 
as shown in Table 1. 14-deoxy-11, 12-didehydroandrographolide, 
and neoandrographolide interact with the target protein in a similar 
pattern. Their interaction with the target majorly happens through 
the similar binding pattern with the same amino acids and at the same 
positions namely Thr 408 A, Gln 409A, Thr 177 B, and His 178 B (Fig. 2).
Lipinski’s rule of five
The bioavailability of the phytoconstituents and standard drug were 
calculated based on the Lipinski’s rule of five, and the results were 
shown in Table 3.
DISCUSSION
In recent scenario, computational techniques such as molecular docking 
tools are used to design novel lead molecules by exploring the interaction 
between the protein and the ligand molecules [19]. The docking results 
predict that the phytoconstituents from A. paniculata have effective 
interaction with the target protein. The compound neoandrographolide 
showed more potent inhibitory activity against MAO-B protein. 
Neoandrographolide is a naturally occurring compound present in A. 
paniculata nees and possesses a wide range of biological application 
because of its anti-inflammatory activity. The interaction of the compound 
with the target protein was analyzed using Molegro viewer module.
As evident from the Table 2, the MolDock score, Re-rank score, 
and H-bond score for the compounds, such as 14-deoxy-11,12-
didehydroandrographolide, andrographoside, neoandrographolide, 
and stigmasterin, were higher. Neoandrographolide had the maximum 
score (126.78 Kcal/mol) with the highest value of H-bond interaction 
(−14.3599 Kcal/mol) and showed a greater affinity for the target 
protein. The activity of the compound neoandrographolide was 
greater compared to that of the standard drug Zelapar, which is used 
commercially for the treatment. Compounds such as androgrpahan and 
14-deoxyandrographolide showed a very less MolDock score and hence 
have a very less affinity for the target. Development of neandrographlide 
as a potential inhibitor would assist in effective medication for the 
disease with minimal or lesser toxic side effects.
CONCLUSION
The present molecular docking studies provide insights into inhibition 
of MAO-B by phytoconstituents from A. paniculata. Docking study 
proposes that neoandrographolide has a high binding affinity for MAO-B 
protein. This study has led to the development of novel lead molecules 
which would help to develop enzymatic mechanisms allowing tumors 
to resist or escape immune rejection.
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Fig. 2: (a) Interaction of 14-deoxy-11, 
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(MAO-B) protein, (b) interaction of andrographoside with MAO-B 
protein, (c) interaction of neoandrographolide with MAO-B 
protein, (d) interaction of Zelapar (standard drug) with MAO-B 
protein visualized using Molegro viewer
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